Pemazyre (pemigatinib) — Medica

Initial criteria

• age ≥ 18 years
• unresectable locally advanced, gross residual, or metastatic disease
• tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement detected by an approved test
• previously treated with at least one systemic regimen

Approval duration

1 year